Phase II Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in R/R MM Pts After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2018
At a glance
- Drugs Bendamustine (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2018 Status changed from recruiting to completed.
- 15 Jan 2015 Planned End Date changed from 1 Jan 2014 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
- 28 Jan 2014 New source identified and integrated.European clinical trial Database.